A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma

Inclusion Criteria * Patients must have biopsy-proven AIDS-associated Kaposi's sarcoma. * Evidence of HIV infection as manifested by a positive antibody test. Exclusion Criteria * Active drug or alcohol abuse. Co-existing Condition: Excluded are patients with: * Active opportunistic infections requiring ongoing therapy. * Excluded within 90 days of study entry: * Must be off therapy for Pneumocystis carinii pneumonia (PCP) unless recovered. * Clinically significant cardiac disease, including a history of myocardial infarction or arrhythmia. * Concurrent neoplasms other than basal cell carcinoma of the skin. * Known hypersensitivity to polymycin B or neomycin. Excluded are patients with: * Active opportunistic infections requiring ongoing therapy. * Excluded within 90 days of study entry: * Must be off therapy for Pneumocystis carinii pneumonia (PCP) unless recovered. * Clinically significant cardiac disease, including a history of myocardial infarction or arrhythmia. * Concurrent neoplasms other than basal cell carcinoma of the skin. * Known hypersensitivity to polymycin B or neomycin. Prior Medication: Excluded: * Interferon. * Zidovudine (AZT). * Excluded within 30 days of study entry: * Any biologic modifiers, corticosteroids, cytotoxic chemotherapeutic agents. * Other drugs which can cause neutropenia or significant nephrotoxicity. * Rifampin or rifampin derivatives, or systemic anti-infectives. * Excluded within 90 days of study entry: * Other antiviral agents…